Beyond weight loss, GLP-1 agents reduce circulating insulin levels, attenuate insulin-like growth factor signaling, and lower systemic inflammatory markers
None is FDA-approved for any of the uses being marketed, and the evidence supporting the wellness claims being made for them ranges from limited to essentially nonexistent
Benefits are that they are widely available, have clear dosage and are used in more human studies than a number of the more specialized types
FDA-approved tirzepatide products - Mounjaro and Zepbound - have full FDA approval with their own manufacturing specifications, labeling, and approved indications
What is the Obesity GLP-1 Market Size
Measurement Challenge: Because the voltage variance is so small (often less than 0.2V across 60% of the capacity), using a simple LiFePO4 voltage chart to guess the exact SOC in this middle range can be inaccurate